TransMedics Posts $17.1M Third-Quarter Net Income
TMDX is trading near its 52-week low of $60.105 (15% above the low) on elevated volume (1.8× avg).
Summary
TransMedics reported third-quarter net income of $17.1M, a swing back to profitability after Q2 net income fell 58% on higher operating expenses and new finance lease costs. Third-quarter revenue rose 41% to $203.0M, with product revenue of $113.4M and service revenue of $89.6M, and adjusted EPS came in at $0.51. The company also raised its 2026 revenue guidance to $764M–$774M. The profit rebound matters because the prior quarter showed earnings pressure from spending and lease costs; a return to positive net income suggests that pressure eased.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — TransMedics' Q3 revenue rose 41% to $203.0M, with product revenue $113.4M and service revenue $89.6M; adjusted EPS was $0.51.
At the time of this announcement, TMDX was trading at $68.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $60.11 to $156.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.